Y Wang, Q Xie, H Tan, M Liao, S Zhu, LL Zheng… - Pharmacological …, 2021 - Elsevier
Epigenetics mainly refers to covalent modifications to DNA or histones without affecting genomes, which ultimately lead to phenotypic changes in cells or organisms. Given the …
J Xia, X Qin, L Zhang, S Liu, X Shi, H Ren - Frontiers in Genetics, 2022 - frontiersin.org
Hepatocellular Carcinoma (HCC) is the most frequent malignant tumor of the liver, but its prognosis is poor. Histone acetylation is an important epigenetic regulatory mode that …
Y Shi, G Huang, F Jiang, J Zhu, Q Xu, H Fang… - Frontiers in …, 2022 - frontiersin.org
Background Hepatocellular carcinoma (HCC) is a major public health problem in humans. The imbalance of mitochondrial function has been discovered to be closely related to the …
GG Faura, B Wu, AK Oyelere, S France - Bioorganic & Medicinal Chemistry, 2022 - Elsevier
Establishing structure–activity relationships (SAR) for privileged pharmacophores, such as the indole scaffold, is a key step in the early stages of drug discovery. Herein, we report the …
In developing new cancer medications, attention has been focused on novel epigenetic medicines called histone deacetylase (HDAC) inhibitors. Our understanding of cancer …
HA Lee, KB Chu, EK Moon, FS Quan - Antioxidants, 2021 - mdpi.com
Histone deacetylase inhibitors (HDACi) are emerging as anti-hepatocellular carcinoma (HCC) agents. However, the molecular mechanisms underlying HDACi-induced …
Uncontrolled inflammation is a salient factor in multiple chronic inflammatory diseases and cancers. In this review, we provided an in-depth analysis of the relationships and distinctions …
B Wu, S Tapadar, Z Ruan, CQ Sun, RS Arnold… - bioRxiv, 2024 - biorxiv.org
Hepatocellular cancer (HCC) progression is facilitated by gene-silencing chromatin histone hypoacetylation due to histone deacetylases (HDACs) activation. However, inhibiting …